Fight back with
Felycin®-CA1

(sirolimus delayed-release tablets)

Felycin-CA1 (sirolimus delayed-release tablets) is the first disease-modifying drug that can give hope to owners of cats with subclinical hypertrophic cardiomyopathy (HCM).

AVAILABLE AUGUST 2025 • AVAILABLE AUGUST 2025 • AVAILABLE AUGUST 2025 • AVAILABLE AUGUST 2025 • AVAILABLE AUGUST 2025 • AVAILABLE AUGUST 2025 • AVAILABLE AUGUST 2025 • AVAILABLE AUGUST 2025 • AVAILABLE AUGUST 2025 • AVAILABLE AUGUST 2025 • AVAILABLE AUGUST 2025 •

Meet the first-in-class management for HCM.

Felycin-CA1 is the first and only FDA conditionally approved once-weekly drug for the management of ventricular hypertrophy in cats with subclinical HCM. Read our detailer to learn more about Felycin-CA1.

download detailer

What does Felycin-CA1 do?

In a 180-day study, cats treated with the recommended once-weekly label dose of Felycin-CA1 had a significantly lower maximal heart wall thickness, showing an average reduction of 0.17mm.1

Felycin-CA1’s mode of action

Be First. Be Ready.

Sign up now to be among the first to prescribe Felycin-CA1 as soon as it’s available.

* indicates required fields

Name*
Address*
Email*
Consent*
This field is for validation purposes and should be left unchanged.